From: Early virological failure and HIV drug resistance in Ugandan adults co-infected with tuberculosis
Characteristics | All patients n = 152 | Viral suppression n = 130 | Virological failure n = 22 | P value |
---|---|---|---|---|
Male gender [N, %] | 89 (58.6) | 80 (61.5) | 9 (40.9) | 0.099 |
Age (years) [Median, IQR] | 34.1 (27.0–39.4) | 34 (28.3–38.9) | 34.1 (25.2–40.9) | 0.882 |
CD4 cell count (cells/µl) [Median, IQR] | 285 (150–453) | 317 (170–465) | 130 (43–341) | <0.001 |
Time on ART (months) [Median, IQR] | 6 (5.5–12) | 6 (5.5–11) | 6 (5–24) | 0.157 |
ART regimen [N, %] | 0.194 | |||
TDF-3TC-EFV | 119 (78.3) | 105 (80.8) | 14 (63.6) | |
AZT-3TC-EFV | 29 (19.1) | 22 (16.9) | 7 (31.8) | |
TDF-3TC-ATV/r | 3 (1.9) | 2 (1.5) | 1 (4.6) | |
TDF-3TC-LPV/r | 1 (0.7) | 1 (0.8) | 0 | |
History of ART switch [N, %] | 30 (19.7) | 22 (17) | 8 (36.4) | 0.044 |
Immunological failure [N, %] | 21 (13.8) | 10 (7.7) | 11 (50) | <0.001 |
EFV serum concentration <1 mg/l [N/, %] | 26 (17.7) | 6 (4.8) | 20 (95.2) | <0.001 |
TB outcome [N, %] | 0.004 | |||
Cured/completed | 142 (93.4) | 125 (96.2) | 17 (77.3) | |
Failure | 3 (2.0) | 1 (0.8) | 2 (9.1) | |
Died | 2 (1.3) | 2 (1.5) | 0 | |
Unknown | 5 (3.3) | 2 (1.5) | 3 (13.6) |